Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Head-to-head comparison of Phenibut and Tropisetron — mechanism, side effects, legal status, and pricing.
Phenibut (β-phenyl-GABA) is a non-peptide small-molecule GABA analogue that acts primarily as a GABA-B receptor agonist, with weaker GABA-A activity and secondary binding to the α2-δ subunit of voltage-dependent calcium channels. Developed and approved in Russia/former Soviet states since the 1960s for anxiety, sleep disturbance, and related conditions, it is not FDA-approved and is not a lawful dietary ingredient in the United States; FDA has issued warning letters to supplement marketers. Phenibut is widely documented in case literature for dependence, severe withdrawal syndromes (including delirium and seizures), and is sold in a gray market as an unregulated nootropic despite regulatory action.
Tropisetron is a non-peptide small-molecule indole-tropane carboxylate ester with dual receptor activity: competitive antagonism at 5-HT3 serotonin receptors and partial agonism at α7 nicotinic acetylcholine receptors. Approved in 1992 as a prescription antiemetic (marketed as Navoban outside the United States) for chemotherapy- and radiotherapy-induced nausea and vomiting, it is NOT approved or marketed in the US. Beyond its approved indication, tropisetron has registered human RCT data in fibromyalgia and schizophrenia-associated cognitive deficits; NO validated human dosing exists for cognitive enhancement in healthy individuals. Available from gray-market research-chemical vendors labeled for laboratory research only.
Phenibut
Tropisetron
Category
Legal Status
Mechanism
Side Effects
COA-verified vendors · trust score ≥70 required · single-vial price — bulk/bundle deals may be lower
Phenibut
No pricing data yet.
Check Phenibut prices →Tropisetron
COA corpus from Disclosed Labs — independently tested batches only.
Phenibut
6
COAs
99.9%
Avg purity
4
Labs
Tropisetron
1
COAs
99.8%
Avg purity
1
Labs
No registered interventional clinical trials were found on ClinicalTrials.gov (API totalCount=0). Phenibut was developed and used clinically in Russia beginning in the 1960s for anxiety, sleep disturbance, peri-operative sedation, asthenia, PTSD, stuttering, and vestibular disorders, reflecting legacy regulatory approval abroad rather than FDA-reviewed randomized controlled trial data. Human data otherwise consists of case reports and case series documenting toxicity, dependence, and withdrawal rather than controlled efficacy trials. Rodent studies showed decreased neuronal activation in hippocampus and neocortex, increased neuronal synchronization, and reduced behavioral reactivity/anxiety; rat brain membrane binding studies confirmed R-phenibut binding to the α2-δ subunit of voltage-dependent calcium channels and gabapentin-like anti-nociceptive effects in rodent pain models.
Tropisetron is an approved prescription drug for chemotherapy-/radiotherapy-induced nausea and vomiting. Human RCT data exist for two investigational uses: (a) a randomized, double-blind, placebo-controlled multicenter trial in 418 fibromyalgia patients (5/10/15 mg once daily × 10 days) reported a higher responder rate in the 5 mg arm than placebo; and (b) an 8-week randomized, double-blind, placebo-controlled trial in 40 risperidone-treated schizophrenia patients (10 mg/day add-on) improved P50 auditory gating and sustained visual attention versus placebo. NO validated human dosing exists for cognitive enhancement in healthy individuals. Preclinical findings include: in vitro (Xenopus oocytes) confirmation of α7-selective partial agonism; in vivo (young/aged rats, aged rhesus monkeys) improvements in novel-object-recognition and delayed-match-to-sample accuracy with systemic tropisetron; rat 3-nitropropionic-acid Huntington's model showing improved motor/behavioral deficits and modulation of Nrf2/HO-1, PI3K/Akt, and JAK2/NF-κB signaling; and rat pilocarpine temporal-lobe-epilepsy model demonstrating reduced spontaneous seizures and hippocampal sclerosis via an α7nAChR-dependent (alpha-bungarotoxin-reversible) mechanism.
Phenibut and Tropisetron are both in the Cognitive category and may have overlapping mechanisms. Researchers should review both profiles carefully, understand the mechanisms of action, and monitor the relevant biomarkers when combining compounds in the same class. As always, consult a licensed healthcare provider before making any decisions about combining research compounds.
This platform provides informational tools only, not medical advice. This comparison is for educational purposes only. Consult a licensed provider.
Contraindications
Lab Testing
Key references
Disclosed Labs